[Dalargin--a peptide preparation with cytoprotective action]

Area of Science:

• Pharmacology
• Gastroenterology
• Toxicology

Background:

• Regulatory peptides represent a novel class of regulatory substances with potential clinical applications.
• Opioid peptides and their analogues are of particular interest due to their diverse physiological roles.

Purpose of the Study:

• To investigate the pharmacological actions and potential clinical utility of the novel drug dalargin.
• To evaluate the efficacy of dalargin in various experimental models of disease and injury.

Main Methods:

• Development of dalargin based on the endogenous opioid peptide leucine-enkephalin.
• Assessment of dalargin's effects using experimental models, including cystamine-induced duodenal ulcers, immobilization stress-induced gastric lesions, and carbon tetrachloride (CCl4) poisoning.
• Pharmacological characterization of dalargin's receptor binding and central nervous system penetration.

Main Results:

• An optimal dose of 10 micrograms/kg for dalargin was identified, demonstrating effectiveness in preventing duodenal ulcers and gastric erosions.
• Dalargin reduced liver degeneration in CCl4 poisoning models.
• Higher doses of dalargin resulted in a diminished therapeutic effect ('escape' phenomenon).
• Dalargin primarily binds to delta-receptors, lacks analgesic properties, and does not cross the blood-brain barrier.

Conclusions:

• Dalargin exhibits significant cytoprotective and regenerative properties.
• The drug's mechanism involves delta-receptor binding without central effects.
• Dalargin holds potential for the treatment of internal organ diseases, warranting further clinical investigation.